Patient Commitment

The diseases we address at Imago BioSciences pose great challenges to patients and physicians. We are committed to focusing on areas of serious clinical need, where our unique insights into the relationship between epigenetics and disease can be translated into new treatments for serious or life-threatening diseases.

Myelofibrosis Treatment and the Unmet Need

Myelofibrosis (MF) is a severe and progressive cancer in which mutant hematopoietic stem/progenitor blood cell clones cause fibrosis and scarring of bone marrow. It is a chronic inflammatory condition in which megakaryocytes secrete inflammatory cytokines and growth factors that pathologically destroy bone marrow, impairing hematopoiesis. Median survival post-diagnosis is approximately 5 years.

There are over 50,000 patients diagnosed with MF in US, EU and Japan many of which have a poor quality of life owing to chronic fatigue, anemia, pain, itching, fever and night sweats. There remains a high unmet need for alternative disease-modifying therapies that improve symptom management.


329 Oyster Point Blvd.
3rd Floor
South San Francisco, CA 94080